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ABSTRACT: Introduction: Dystrophinopathies are X-linked mus-
cle degenerative disorders that result in progressive muscle
weakness complicated by bone loss. This study’s goal was to
evaluate feasibility and tolerability of whole-body, low-intensity
vibration (WBLIV) and its potential effects on muscle and bone
in patients with Duchenne or Becker muscular dystrophy. Meth-
ods: This 12-month pilot study included 5 patients (age 5.9–
21.7 years) who used a low-intensity Marodyne LivMD plate
vibrating at 30–90HZ for 10min/day for the first 6 months.
Timed motor function tests, myometry, and peripheral quantita-
tive computed tomography were performed at baseline and at 6
and 12 months. Results: Motor function and lower extremity
muscle strength remained either unchanged or improved during
the intervention phase, followed by deterioration after WBLIV
discontinuation. Indices of bone density and geometry remained
stable in the tibia. Conclusions: WBLIV was well tolerated and
appeared to have a stabilizing effect on lower extremity muscle
function and bone measures.
Muscle Nerve 55: 875–883, 2017
Dystrophinopathy (OMIM #310200) is a muscular
dystrophy with a recessive X-linked inheritance
mode, caused by loss-of-function mutations in the
gene encoding dystrophin.1 The clinical presenta-
tion ranges from more severe manifestations in
Duchenne muscular dystrophy (DMD) to a milder
allelic Becker muscular dystrophy (BMD).2,3 Dys-
trophin is critical for structural stability of myofib-
ers in skeletal, diaphragm, and cardiac muscles.4
In dystrophinopathy, its deficiency compromises
functional integrity of muscle fibers and leads to
progressive weakness manifesting as difficulty run-
ning and walking, rising from the floor, and taking
stairs. Eventually, loss of ambulation, respiratory
insufficiency, and cardiomyopathy ensue and lead
to death due to cardiorespiratory compromise.
During the ambulatory stage of the disease, boys
with dystrophinopathies walk less and at a much
slower pace, are significantly less active than
healthy peers, and are at risk of frequent falls.
A progressive decline in muscle function with
age is accompanied by a decline in bone mineral
density and bone quality, leading to increased
bone fragility and long-bone and vertebral frac-
tures.5–8 In many cases, a bone fracture an inciting
event that ends the ambulatory stage in
these patients. Bone loss in dystrophinopathies is
multifactorial due to reduced physical activity,
immobility, long-term glucocorticoid treatment,
hypogonadism, low vitamin D levels, inflammatory
changes, and other metabolic abnormalities relat-
ed to the disease process.9,10
The primary goal in treating boys with dystro-
phinopathies is to provide supportive measures
through multidisciplinary care. The only accepted
pharmacologic treatment thus far that slows dis-
ease progression is the use of glucocorticoids.11
Unfortunately, long-term use of glucocorticoids is
associated with significant multisystem side effects,
including bone loss.12 Physical and occupational
therapy play a major role, including stretching
exercises to prevent contractures, and assistive
devices to prolong ambulation and maintain inde-
pendence,13 but these interventions do little to
help preserve bone health.
Abbreviations: 6MWT, 6-minute walk test; BMC, bone mineral content;
BMD, Becker muscular dystrophy; BSI, bone strength index; CSA, cross-
sectional area; DMD, Duchenne muscular dystrophy; ISO, International
Standards Organization; pQCT, peripheral quantitative computer tomogra-
phy; TFT, timed function test; vBMD, volumetric bone mineral density;
WBLIV, whole-body, low-intensity vibration
Key words: Becker muscular dystrophy; Duchenne muscular dystrophy;
myometry; pQCT; timed function test; vibration
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Mechanical vibration has gained considerable
interest as a way to improve muscle function and
serve as a bone-sparing strategy in children with
disabling conditions, such as cerebral palsy,14–16
osteogenesis imperfecta, or spinal dysraphism.17
However, clinicians have been hesitant to use
mechanical vibration in patients with dystrophino-
pathies due to concern about possible further
damage to the diseased muscle.18–22 A number of
whole-body vibration platforms are currently avail-
able, which vary in terms of vibration intensity
(expressed in g-force, or “g”)23 and mode of vibra-
tion transmission (synchronous, meaning applied
to both feet at the same time, or side-alternating).
Low-intensity vibration devices deliver a force <1g
(1g is earth’s gravitational field), whereas high-
intensity vibration devices deliver acceleration
intensity >1g (as high as 16.3g). In some cases, this
exceeds the safety threshold limit values estab-
lished by the International Standards Organization
(ISO-2631), depending on the vibration frequency
and duration of exposure.23,24
In recent years, 3 pilot studies have been pub-
lished that examine the safety of whole-body vibra-
tion in patients with DMD using high-intensity,
side-alternating vibration platforms (Galileo train-
ing) for 4 weeks to 3 months, with varied target
vibration frequencies of 15–24 HZ.25–27 These stud-
ies concluded that whole-body vibration treatment
was safe and tolerated by these patients, although
its effect on bone and muscle was inconclusive.
None of the published studies addressed the
effects of a low-intensity vibrating platform in
patients with DMD or BMD. Novotny et al. first
investigated this approach in a preclinical study
using the mdx mouse model for DMD.28 The mdx
mice were subjected to low-magnitude, whole-body
vibration at a frequency of 30–90 HZ, based on our
previous work that identified 45 HZ as most effec-
tive at increasing the expression of osteogenic
genes.29 There was no evidence of loss of force
generation or any other parameter of muscle con-
tractility measured during 8 weeks of vibration
training, which supported the notion that whole-
body, low-magnitude vibration (WBLIV) is not del-
eterious to dystrophic muscles30 and has the poten-
tial to improve muscle contractility.
The primary aim of this pilot study was to test
the feasibility and tolerability of low-intensity vibra-
tion as a therapeutic approach for patients with
dystrophinopathies using a portable Marodyne
LivMD plate that delivers WBLIV with an oscillat-
ing frequency of 30–90 HZ, at a maximum g-force
of 0.4g, which is well within the ISO threshold lim-
it values.23,24 We hypothesized that this type of
intervention would be feasible and well tolerated
without adverse effects on the function of the
lower extremity muscles with the greatest exposure
to vibration. The secondary aim was to examine
the effects of WBLIV on bone density, geometry,
and strength of the tibia and radius. Because that
transmissibility of vibrations is the highest to tis-
sues closer to the source,31 the hypothesis was that
the intervention would stabilize bone measures of
the tibia but not the radius during the vibration
intervention phase of the study.
METHODS
Participants. Participants were male patients (5.9–
21.7 years old) with DMD or BMD confirmed
through clinical examination and genetic testing,
ambulatory (able to walk 75 meters unassisted),
and not dependent on daytime ventilatory support.
Exclusion criteria were treatment with human
growth hormone or bisphosphonates, fracture with-
in the last 4 weeks, or inability to stand for 10
minutes on flat feet. The participants were recruited
from the Muscular Dystrophy Clinic at the Universi-
ty of Minnesota. Females who were manifesting car-
riers were not included due to minimal clinical
manifestations. The study protocol was approved by
the institutional review board at the University of
Minnesota and was consistent with the requirements
of the Declaration of Helsinki.
Study Procedures. The study design included 2
baseline evaluations 2 weeks apart, followed by a 6-
month intervention period and a subsequent 6-
month follow-up period. At the initial visit, each
patient underwent a physical examination with
anthropometry and Tanner staging of pubertal
development based on testicular volume (by
orchidometer) and pubic hair, with the higher of
the 2 values being recorded. Baseline, 6-month,
and 12-month evaluations included timed motor
function tests, quantitative myometry, and periph-
eral quantitative computed tomography (pQCT) of
the tibia and non-dominant radius.
Intervention. Each participant was given a por-
table Marodyne LivMD plate adjusted for lower
weight (Marodyne Medical, Inc., Lakeland, Flori-
da) to be used at home while free standing for 10
consecutive minutes per day,32 7 days per week for
6 months. The Marodyne LivMD plate is designed
to deliver low-magnitude (0.4g), high-frequency
vibration with an oscillating frequency of 30–90 HZ.
Both participants and their caregivers were trained
in the proper use of the vibratory plate. The first
treatment was completed in the clinic after all
baseline measurements were taken to demonstrate
proper use of the plate. The second treatment
took place at the subject’s home the next day. The
study coordinator called the participants every 2
weeks to ensure compliance. Information about
other interventions, including night-time splints,
876 Whole-Body Vibration in Dystrophinopathies MUSCLE & NERVE June 2017
stretching, glucocorticoids, and novel drugs, is pre-
sented in Table 1.
Functional Assessment. The 6-minute walk test
(6MWT) was originally designed for adults, and for
this reason it has been modified to fit the needs of
children with muscular dystrophy.33 This version
has been shown to be a reliable and valid measure
of ambulation as well as safe and easy to perform
in patients with dystrophinopathies without severe
cognitive or behavioral problems. It is a submaxi-
mal exercise test, and because most activities of
daily living are performed at a submaximal level,
6MWT reflects function. Briefly, the 6MWT was
assessed using a 25-meter taped line with 1-meter
marked intervals and cones at each end of the
tape to mark the ambulatory path. Arrows were
placed at the end of the cones in a counterclock-
wise direction to define the direction of ambula-
tion. Continuous moderate verbal encouragement
was allowed throughout the testing period. In addi-
tion, a “safety chaser” followed the child through-
out the test to keep him on the correct path, to be
in close proximity in case of a fall to help him to a
standing position, or to tend to him quickly if an
injury occurred. The following timed function tests
(TFTs) were also performed: the time-to-run/walk
test, measuring the time (in seconds) to walk or
run, if possible, a distance of 10 meters; the time-
to-climb-4-stairs test, measuring the time (in sec-
onds) to ascend 4 standard stairs; and the supine-
to-stand test, measuring the time (in seconds) for
the child to assume a standing position from a
supine starting position.34,35
Quantitative Myometry. Strength testing includ-
ed quantitative myometry using a handheld dyna-
mometer (PowerTrack II Commander; JTech
Medical, Midvale, Utah) to measure the maximum
voluntary isometric force during muscle contrac-
tion of ankle plantar flexion, ankle dorsiflexion,
hip flexion, knee flexion/extension, and elbow
flexion/extension.36 Values were recorded as New-
tons of force. Participants were asked to perform
each test bilaterally, and the average of the 2
forces produced was used in analyses.
Peripheral Quantitative Computed Tomogra-
phy. Measures of cortical and trabecular bone and
estimated bone strength were obtained using
peripheral quantitative computed tomography
(pQCT; XCT-3000; Stratec Medizintechnik GmbH,
Pforzheim, Germany). Images were taken at the
distal 3% and 33% of the non-dominant radius
with a scan speed of 20 mm/s. The distal 3% and
38% sites of the tibia were scanned at 25 mm/s. All
scan sites had a section thickness of 2.4 mm and a
voxel size of 0.4 mm. The reference line for both
tibia and radius was placed at the proximal end of
the distal growth plate using a scout view speed of
50 mm/s with a 1-mm step width. Image processing
and calculation of bone parameters were complet-
ed using the manufacturer’s software (version 6.0).
Phantom scanning was done daily for quality
control.
Bone outcome measures37 at metaphyseal sites
included trabecular volumetric bone mineral den-
sity (vBMD; mg/cm3), trabecular cross-sectional
area (CSA; mm2), and total bone strength index
(BSI; mg2/mm4) using contour mode 3 with a
threshold of 169 mg/cm3 and peel mode 4 thresh-
old 650 mg/cm3 with 10% concentric peel at the
tibia and 15% at the radius. At diaphyseal sites, the
measures included cortical vBMD, cortical CSA,
cortical bone mineral content (BMC; mg/mm),
and cortical thickness (mm), using cort mode 2
with a threshold of 710 mg/cm3. Non-weighted
polar section modulus (mm3) and strength
strain index (mm3) were measured at the 38% tib-
ia site using cort mode 2 with a threshold of
480 mg/cm3.
Table 1. Patients’ characteristics at baseline
Patient 1 Patient 2 Patient 3 Patient 4* Patient 5 Patient 6
Age (years) 5.9 7.5 12.4 9.8 21.7 16.4
Tanner stage 1 2 2 1 5 5
Height (Z-score) –2.2 –2.0 –3.6 –0.1 0.3 –0.7
BMI (kg/m2) 14.8 18.2 21.0 14.7 29.2 23.7
BMI (Z-score) 20.5 1.2 1.0 21.2 1.7 0.9
Diagnosis DMD DMD DMD DMD BMD BMD
Gene mutation Dup exon 49,
OOF
Del 55,
OOF
Exon 32, c.4414T,
p.Q1472X, OOF
Dup exon 2,
OOF
Del exon 3–7,
IF
Del exon 3–7,
IF
Interventions in
addition to
WBLIV
DFZ, NTS,
stretching
DFZ, NTS,
stretching
DFZ, NTS,
staluren, stretching
Pred, NTS,
stretching
Stretching Stretching
BMD, Becker muscular dystrophy; DFZ, deflazacort; DMD, Duchenne muscular dystrophy; Del, deletion; Dup, duplication; IF, in-frame; OOF, out-of-frame;
WBLIV, whole-body, low-intensity vibration; NTS, night-time splint; Pred, prednisone.
*Dropped out of the study after 2 weeks due to worsening headaches.
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Statistical Analysis. For each outcome measure,
the statistical analysis included a mixed linear mod-
el to account for correlation of multiple visits within
person, with random-effect person and fixed-effect
visit. In the analysis, the 2 baseline evaluations were
included as separate visits; changes from baseline to
6 or 12 months were estimated and tested as con-
trasts in the visit fixed effect, specifically as the 6-
month visit (or 12-month visit) minus the average
of the 2 baseline visits. A measure’s percent change
was calculated from 0 to 6 months, from 6 to 12
months, and from 0 to 12 months. No adjustments
were made for multiple testing, because these
results are preliminary and because the primary
interest is in the broad pattern of results, not results
for individual measures. All analyses were
performed using JMP software (JMP version 12 Pro;
SAS Institute, Inc., Cary, North Carolina).
RESULTS
Study Participation. Six patients were enrolled in
the study. One patient (patient 4) with attention defi-
cit hyperactivity disorder and a prior history of head-
aches had worsening headaches during the first 2
weeks of intervention. Although headaches were
deemed unrelated to the study, he found the exercise
routine an excessive burden and dropped out after 2
weeks. The remaining 5 patients completed the study
and did not report any difficulty with using the plat-
form, muscle pain, cramps, or any other adverse
events. Table 1 shows characteristics of all 6 patients.
None of the patients had fractures.
Table 2. Timed motor function tests before and after 6 months of vibration training and 6 months after discontinuation of vibration
Time-points Estimated change6SE and percent change
0 6 months 12 months 0–6 months % 6–12 months % 0–12 months %
6-min walk (m) 412 395 396 216.8612.0 24.1 0.86 13.9 0.2 216.06 12.0 23.9
10-m walk (s) 5.6 6.0 7.0 0.460.5 6.4 1.06 0.6 16.2 1.36 0.5 23.6*
Stair climb (s) 4.0 3.9 6.8 20.160.4 22.9 2.96 0.5‡ 74.8‡ 2.86 0.4‡ 69.9‡
Supine to stand (s) 6.3 6.5 11.1 0.261.6 3.9 4.66 1.9a 70.9* 4.96 1.6† 77.6†
Data are shown as adjusted means, estimated change6 standard error (SE), and percent change.
*P< 0.05; †P< 0.01; ‡P< 0.001.
FIGURE 1. Plots of selected timed motor function tests and myometry for individual patients. Dashed lines: patients with Becker mus-
cular dystrophy; solid lines: patients with Duchenne muscular dystrophy. DF, dorsiflexion; PF, plantar flexion.
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6-Minute Walk Test. Overall, 6MWT results showed
no significant change in distance walked over the
course of this study. When analyzed for individual
participants, the 6MWT results were consistent
with the natural history reported previously38 and
predicted by baseline distance, age, or genetic
mutation (out-of-frame vs in-frame). Patient 3 had
an out-of-frame mutation and had a decline in the
distance by 53 meters over the course of 12
months from 369 to 316 meters, which is consis-
tent with the expected decline because of his base-
line distance. Another participant (patient 2)
showed a decline of 28 meters from 410.3 to 382
meters. The results for the remaining 3 partici-
pants were essentially unchanged.
Timed Function Tests. Motor function remained sta-
ble in all TFTs during the 6 months of intervention
with WBLIV, followed by deterioration during the
subsequent 6 months without WBLIV, which is con-
sistent with the expected progressive deterioration
in muscle function over time in dystrophinopa-
thies. The time-to-climb-4-stairs test showed a
74.8% longer time at 12 months compared with 6
months. The time-to-stand test showed 70.9% lon-
ger time at 12 months compared with 6 months
(Table 2 and Fig. 1). In both tests, 4 of 5 partici-
pants showed significant (>10%) increases in time
after WBLIV was discontinued at 6 months. Only
1 patient with BMD, who had the best function in
this group (patient 6), remained unchanged. The
changes from baseline to 12 months were also sig-
nificant. Although performance in the 10-meter
walk test did not change significantly during the
intervention phase (0–6 months), the walking
time was 23.6% longer at 12 months compared
with baseline. In this test, only 3 patients showed
an increase in time of >10%, and 2 remained
unchanged.
Muscle Strength Testing. Muscle strength was mea-
sured by quantitative myometry. Elbow flexion
Table 3. Myometry before and after 6 months of vibration training and 6 months after discontinuation of vibration
Time-points Estimated change6SE and percent
0 6 months 12 months 0–6 months % 6–12 months % 0–12 months %
Elbow flexion 46.8 34.9 36.5 211.96 4.7* 225.4* 1.665.4 4.5 210.36 4.7* 222.1*
Elbow extension 33.2 36.3 32.5 3.26 2.8 9.5 23.863.2 210.4 20.66 2.8 21.9
Hip flexion 57.6 67.7 56.9 10.16 5.0 17.6 210.865.8 216.0 20.76 5.0 21.2
Knee flexion 50.0 53.2 56.3 3.26 4.0 6.4 3.064.6 5.7 6.36 4.0 12.5
Knee extension 60.0 59.6 63.2 20.46 5.5 20.7 3.666.4 6.0 3.26 5.5 5.2
Ankle dorsiflexion 44.4 46.4 34.6 2.06 5.7 4.5 211.866.5 225.4 29.86 5.7 222.0
Ankle plantar flexion 44.0 51.1 52.4 7.06 3.2* 16.0* 1.363.7 2.6 8.46 3.2* 19.0*
Data are shown as adjusted mean (expressed in Newtons of force), estimated change6 standard error (SE), and percent change.
*P< 0.05.
Table 4. pQCT bone measures for the radius before and after 6 months of vibration training and 6 months after
discontinuation of vibration
Time-points Estimated change6SE and percent change
0 6 months 12 months 0–6 months % 6–12 months % 0–12 months %
Trabecular
vBMD
224.1 211.0 203.0 –13612.9 25.8 27.66 13.6 23.6 220.6621.1 29.2
Trabecular
CSA
206.8 196.0 175.0 210.56 42.7 25.1 221.1645.0 210.8 231.7669.9 215.3
Cortical
vBMD
1,143.5 1,146.0 1,151.0 2.46 23.7 0.2 4.76 24.7 0.4 7.16 37.3 0.6
Cortical
CSA
68.5 64.0 65.0 24.76 1.5* 26.8* 0.96 1.6 1.3 23.862.4 25.6
Cortical
BMC
79.1 73.8 74.8 25.36 1.8* 26.7* 1.16 1.9 1.4 24.262.9 25.4
CT 2.92 2.78 2.80 20.146 0.05* 24.8* 0.026 0.05 0.7 20.1260.08 24.1
BSI 31.8 27.0 26.0 24.36 1.9* 213.6* 21.261.9 24.2 25.563.1 217.2
Zp 186.7 179.0 180.0 27.36 5.6 23.9 0.26 5.9 0.1 27.168.8 23.8
SSI 154.7 154.0 156.0 20.26 5.2 20.1 1.96 5.8 1.2 1.66 8.2 1.0
Data are shown as adjusted means for the radius length, estimated change6 standard error (SE), and percent change. BMC, bone mineral content (mg/
mm); BSI, bone strength index (mg2/mm4); CT, cortical thickness (mm); CSA, cross-sectional area (mm2); vBMD, volumetric bone mineral density (mg/
cm3); Zp, polar section modulus (mm3); SSI, strength strain index (mm3).
*Significant change, P< 0.05.
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strength decreased by 25.4% in the first 6 months
compared with baseline and remained below base-
line at 12 months (by 22.1%, Table 3) with changes
more pronounced in patients with BMD (Fig. 1).
There was no change in elbow extension strength
(Table 3). Among lower extremity measures, ankle
plantar flexion strength improved by 16% during
the 6-month intervention period and remained
above baseline at 12 months (19%). All participants
showed an increase in ankle plantar flexion
strength, ranging from 8% to 48% when compared
with baseline. Ankle dorsiflexion strength remained
stable during the intervention phase and decreased
by 25.4% after discontinuation of vibration training,
although this change was not statistically significant.
There was also a trend toward an increase in force
in hip flexion during WBLIV (by 17.6%), followed
by a 16% decrease toward baseline over the next 6
months (Table 3); these changes were also more
apparent in patients with BMD. Overall, measures
of upper extremity strength were either no different
or worse over the 6-month intervention period,
whereas measures of lower extremity strength were
either stable or showed increased force after the 6-
month intervention phase.
Bone Measures with Peripheral Quantitative
Computed Tomography. Measures of bone density
and geometry of the radius are shown in Table 4.
Downward trends were noted in most measures,
with statistically significant decreases in the cortical
CSA, cortical BMC, cortical thickness, and BSI dur-
ing the first 6 months followed by no significant
changes during months 6–12.
In the tibia, there was a trend toward an
increase in trabecular CSA during the intervention
phase (by 25% compared with baseline; Table 5).
Other indices of bone geometry and strength did
not change significantly.
DISCUSSION
In this pilot study of 5 patients with dystrophi-
nopathies, we have shown that intervention with
low-intensity vibration using a portable Marodyne
LivMD plate was well tolerated by ambulatory
patients with DMD or BMD, without adverse effects
on the function of the lower extremity muscles
with the greatest exposure to vibration. The
patients did not experience increased fatigue, mus-
cle soreness, cramps, falls, or fractures. The porta-
bility and ease of use of a WBLIV plate made it
suitable for use at home on a daily basis and with-
out a therapist.
Motor capacity measured by TFTs remained sta-
ble during the 6 months of WBLIV intervention,
followed by deterioration in the time-to-climb-4
stairs test and the time-to-stand test after discontin-
uation of vibration training, suggesting that WBLIV
does not have deleterious effects and may have a
stabilizing effect on muscle function. Lack of
appreciable change in the 6MWT may have been
due to small sample size or variability in the natu-
ral history. Longitudinal studies have shown that
boys <7 years of age with DMD typically have an
increase in 6MWT over a year, whereas boys >7
years of age may have more of a plateau or decline
in 6MWT performance.33,38 There is little to no
information about the changes expected in 6MWT
over 6–12 months in patients with BMD.
Measures of muscle strength by quantitative
myometry in the lower extremities were either sta-
ble or showed a trend for improvement during the
6-month intervention phase, particularly in hip
flexion and ankle plantar flexion strength.
Although not statistically significant, an increase of
18% in hip flexion during the 6 months of the
intervention is intriguing and suggests a positive
trend. These results are corroborated by the time
to climb 4 stairs, which showed an increase in 4 of
5 boys after discontinuation of intervention.
Table 5. pQCT bone measures for the tibia before and after 6 months of vibration training as well
as 6 months after discontinuation of vibration
Time-points Estimated change6SE and percent change
0 6 months 12 months 0–6 months % 6–12 months % 0–12 months %
Trabecular vBMD 201.2 207.0 199.0 6.265.4 3.1 28.56 6.2 24.1 22.26 8.1 21.1
Trabecular CSA 544.0 680.0 627.0 136.1666.7 25.0 252.86 75.8 27.8 83.36 99.9 15.3
Cortical vBMD 1,111.6 1,129.0 1,134.0 17.0625.1 1.5 5.76 28.3 0.5 22.76 35.4 2.0
Cortical CSA 178.8 175.0 171.0 23.667.2 22.0 24.06 8.1 22.3 27.66 10.2 24.2
Cortical BMC 202.2 198.5 195.8 23.767.4 21.8 22.76 8.4 21.4 26.46 10.5 23.2
CT 3.99 4.01 3.97 0.036 0.1 0.8 20.046 0.11 21.0 20.026 0.14 20.5
BSI 60.8 60.0 58.0 21.061.5 21.6 21.66 1.7 22.7 22.66 2.2 24.3
Zp 1042.7 998.0 928.0 244.8646.9 24.3 270.16 53.0 27.0 2115.06 66.3 211.0
SSI 928.1 886.0 834.0 241.6637.0 24.5 252.26 41.9 25.9 293.86 52.3 210.1
Data are shown as adjusted means for the tibia length, estimated change6SE, and percent change. BMC, bone mineral content (mg/mm); BSI, bone
strength index (mg2/mm4); CT, cortical thickness (in mm); CSA, cross-sectional area (mm2); vBMD, volumetric bone mineral density (mg/cm3); Zp, polar
section modulus (mm3); SSI, strength strain index (mm3).
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Likewise, stabilization of ankle dorsiflexion after
the intervention phase suggests a positive trend as
compared with a 25% decrease in force after a 6-
month period without intervention. In contrast, no
trends for improvement were observed in muscle
strength of the upper extremities. WBLIV
appeared to have a stabilizing effect on the pQCT
measures of bone density and geometry of the tib-
ia, and less so of the radius.
There is a suggestion of a differential effect of
WBLIV on upper vs. lower extremity muscle
strength and bone indices with a trend for
improvement in both muscle and bone measures
in the lower extremities. This may have been due
to a positive effect of WBLIV on skeletal muscle tis-
sue and bone in close proximity to the vibrating
platform. This finding is consistent with other stud-
ies showing that skeletal regions closest to the
source of vibration have more robust responses39
compared with distal sites, where transmission is
diminished.31 The decrease in biceps strength dur-
ing the first 6 months of intervention was likely
due to natural disease progression. In fact, the pur-
pose of assessing the upper extremities in this
study was to have an “internal” control for disease
progression. This change is less likely to represent
a deleterious effect of vibration because of its dis-
tance from the vibrating platform. However, this
finding should be explored further in future
studies.
In this investigation we have examined the
effects of a low-intensity synchronous vibrating
platform. Three previous studies performed on
boys with DMD used a high-intensity, side-alternat-
ing vibration platform.25–27 These 3 studies aimed
primarily to examine safety and tolerability of
vibration training, and all found whole-body vibra-
tion to be feasible and safe, similar to our study
and consistent with our preclinical observations.28
Besides using a different platform, the earlier stud-
ies used a shorter duration of vibration training
and a lower frequency of vibration.
In the first study, from Sweden,26 6 ambulatory
patients with DMD used whole-body vibration (at
16–24 HZ) for up to 6 minutes, 2 or 3 times weekly
for 3 months. No changes in trabecular or cortical
density of the tibia, muscle strength, motor func-
tion, or bone turnover markers were observed,
except for a trend toward an increase in a bone-
specific alkaline phosphatase level and muscle den-
sity (by pQCT). The lack of a noticeable positive
effect of vibration training on muscle and bone
was thought to be due to small sample size, low
vibration frequency, or short duration of training.
The second study, from Canada,27 involved 4
ambulatory patients with DMD who participated in
vibration therapy sessions (target frequency 20 HZ),
each consisting of vibration 2 minutes on, 60 sec-
onds off, 2 minutes on, 3 times per week during a
4-week training period, without any resultant major
changes in functional mobility. The third study,
from Germany,25 included 14 ambulatory boys
with DMD and 8 with spinal muscular atrophy.
Galileo training (target frequency 15–18 HZ) was
performed for 9 minutes, twice a day for 5 days
per week for 8 weeks. Although no clear statistical-
ly significant effect of whole-body vibration train-
ing was observed on muscle strength, function, or
flexibility, some positive trends were noted. For
example, patients with DMD had small improve-
ments in 6MWT, stair-climb test, muscle strength
of the legs (knee myometry and ankle dorsiflex-
ion), and angular degree of ankle dorsiflexion.
These trends suggest that a longer training
period may be needed to see a greater impact of
vibration training. Overall, the effect of whole-body
vibration on bone and muscle using a side-
alternating vibration platform for 4–18 min/day, 2–
5 times weekly for 4 weeks to 3 months, with target
vibration frequencies of 15–24 HZ, was considered
indeterminate.
We chose a 10-minute duration of low-intensity
vibration training based on previous reports that
low-magnitude, high-frequency, whole-body vibra-
tion treatment for 10 min/day resulted in increases
in both bone and muscle mass in young women
with low bone mineral density.32 The vibration fre-
quency delivered by the Marodyne LivMD plate,
30–90 HZ, is similar to the frequency found to be
safe and without deleterious effects on diseased
muscle in an mdx mouse model of DMD.28 Recent
data show that, although high-intensity training
induces muscle damage in mdx mice, low-intensity
training reduces the level of protein carbonylation,
a marker of oxidative damage, and rescues the mdx
phenotype.40 The duration of daily vibration thera-
py in our study was 6 months, which is the longest
intervention so far and which could explain some
of the promising positive effects on muscle func-
tion and strength. Our data further suggest that
this intervention may need to continue long term
to maintain the improvements observed.
Other forms of physical training have also
shown promise in delaying functional deterioration
in patients with dystrophinopathies. For example,
in a randomized, controlled trial in 30 boys with
DMD that involved assisted bicycle training for 24
weeks, the motor function measure score remained
stable in the intervention group, yet it decreased
significantly in the control group.41 In the control
group, 3 boys lost the ability to walk 10 meters,
and 2 boys lost the ability to rise from the floor. In
the intervention group, none of the boys lost the
ability to walk 10 meters, and only 1 boy lost the
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ability to rise from the floor during the training
period. Range of motion remained relatively sta-
ble in the intervention group during the training
period. Likewise, resistance training of upper and
lower extremity muscles can increase muscle
strength in muscular dystrophies, as shown by
Sveen et al.,42 who assessed 2 patients with BMD
and 6 with limb-girdle muscular dystrophy. They
found that elbow flexion and knee extension
improved significantly after 6 months of low-
intensity resistance training.
The limitations of this and other studies
include a small sample size, heterogeneous patient
populations, and absence of matched controls.
The analyses were necessarily exploratory and did
not adjust for multiple comparisons. Although our
study demonstrated the feasibility and tolerability
of this approach in patients with dystrophinopa-
thies, any observable positive effects on muscle and
bone, albeit encouraging, should be considered
preliminary. The findings lay the groundwork for a
larger, controlled trial to establish effective vibra-
tion parameters for a given type of platform, tak-
ing cost and portability into account. Because any
biological effect of vibration is likely to decrease
with increasing distance from the synchronous
vibrating platform, a supplemental device that can
be placed on the elbows16 or supplemental upper
extremity exercise training may be needed.43 Vry
et al.25 showed that at least a portion of the clini-
cally significant increase in joint flexibility could
be attributed to mechanical stretching due to
vibration. Thus, consideration should be given to
supplementing traditional physiotherapy with
whole-body vibration as future rehabilitative
approaches.
The authors thank Dr. Jamie Marsh, who performed assessments
of muscle function and strength; Rebecca Hollister and Alise
Thone for technical assistance with pQCT scanning; and the
patients and their families for participation in the study.
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